InvestorsHub Logo
Followers 13
Posts 2494
Boards Moderated 0
Alias Born 02/04/2014

Re: None

Tuesday, 07/27/2021 3:31:17 AM

Tuesday, July 27, 2021 3:31:17 AM

Post# of 326
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

insert-text-here

https://www.obseva.com/pressrelease-detail/?pr=4394&doing_wp_cron=1627370494.5277700424194335937500
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OBSV News